title: [Male breast cancer: a challenge for urologists].
abstract: Male breast cancer (male BC) accounts for <1% of all cancers in men, showing an increasing incidence with a peak in the sixth decade. Overall, men experience a worse prognosis than women, probably due to an advanced stage together with the higher age at diagnosis of male patients. Major risk factors for developing male BC include clinical disorders involving hormonal imbalances (excess of estrogen or a deficiency of testosterone as seen in patients with Klinefelter syndrome) and a positive family history for breast cancer. About 90% of male BC are invasive ductal carcinomas. Standard treatment for localized cancer is surgical removal. Adjuvant radiation and systemic therapy are the same as in women with breast cancer. Male BC expresses hormone receptors in about 90% of cases; therefore, tamoxifen is a therapeutic option. A future challenge for the urologist or andrologist is to diagnose the disease at an early stage to improve prognosis.
authors: Urologische Gemeinschaftspraxis Odeonsplatz, Odeonsplatz 2, 80539, München, Deutschland. drhofer@urologie-odeonsplatz.de
authors: C
authors: C
authors: Hofer
authors: B
authors: B
authors: Schmalfeldt
authors: J E
authors: JE
authors: Gschwend
authors: K
authors: K
authors: Herkommer
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D018567:Breast Neoplasms, Male / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D003950:Diagnostic Techniques, Urological; D006801:Humans; D008297:Male; D015995:Prevalence; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D013629:Tamoxifen